Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-07-21
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines, anchored by CASGEVY with Vertex and a wholly owned pipeline spanning autoimmune, oncology, cardiometabolic and rare diseases.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved editing, but platform proof still gates rerating
The company now has a real commercial floor, not just a science story. By 2031 the upside depends on whether broader CASGEVY access and at least one owned branch turn gene-editing credibility into a second real franchise.

Analysis

Thesis
CRISPR Therapeutics has already crossed the hardest credibility gate with the first approved CRISPR therapy; if CASGEVY’s broadened label lifts the commercial floor and just one owned branch such as CTX310, zugo-cel or CTX611 becomes clearly reproducible in humans, the stock can rerate from cash-backed optionality to a multi-franchise gene-editing platform by 2031.
Last Economy Alignment
AI should speed design, assay learning and portfolio throughput, while CRISPR still captures value through IP, approvals and regulated manufacturing rather than software seats. The limiter is that physical treatment, partner control and regulators still gate scale.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.8x (from 5 most recent analyses)
Reasoning
The upside case does not require every program to work. A higher CASGEVY floor from broader age eligibility and reimbursement progress, plus one owned clinical branch graduating into a credible commercial franchise, is enough for a 2x-5x outcome. The balance sheet buys time, but the rerating still depends on converting scientific breadth into productized revenue outside the Vertex-led asset.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not immediate liquidity. CRISPR needs CASGEVY to become a repeatable cash engine and at least one owned program to deliver durable human efficacy with clean enough safety to support commercial value; otherwise the company remains a partner-dependent approved product plus a portfolio the market values mostly as scientific optionality.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.38
They already control scarce gene-editing know-how, regulatory credibility and some manufacturing capability, so AI mostly helps them design and learn faster rather than replacing them. The catch is that patients, hospitals, partners and regulators still decide the pace, so this flywheel compounds slower than pure software.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$84.70
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case